AF
PTCT icon

Arrow Financial’s PTC Therapeutics PTCT Stock Holding History

Arrow Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-204
Closed -$10K – 343
2015
Q2 		$10K Hold
204
– – ﹤0.01% 274
2015
Q1 		$12K Buy
+204
New +$12.4K ﹤0.01% 271

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Arrow Financial's PTCT Position: Q3 2015 in Review

Arrow Financial sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 204 shares — an estimated $10K sold.

Arrow Financial first reported a position in PTCT in Q1 2015 and held it in 2 quarters. The position peaked at $12K in Q1 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

  • Arrow Financial reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Arrow Financial sold 204 PTC Therapeutics shares in Q3 2015, an estimated $10K.
  • Arrow Financial first reported a position in PTC Therapeutics in Q1 2015 and held it in 2 quarters.
  • Arrow Financial's PTC Therapeutics position peaked at $12K in Q1 2015.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on Arrow Financial's 13F filing for Q3 2015, filed 6 Nov 2015.